AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. AstraZeneca is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines. For more information please visit: http://www.astrazeneca.com.
1. FASLODEX Prescribing Information Available online [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... Last accessed October 05 ]. Last accessed October 05, 2012.
2. Robertson JFR, Llombart-Cussac A, Rolski J, et al., Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study. Journal of Clinical Oncology. 2009;27(27): 4530-4535.
3. Ferlay J et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France, International Agency for Research on Cancer, 2010 Available online [http://globocan.iarc.fr/factsheet.asp ]. Last accessed September 19, 2012.
4. Robertson J, Ellis M. A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON). Clinical Study Protocol Synopsis. Study Code D699BC00001. May 1, 2012.
5. ClinicalTrials.gov. A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (FALCON) Available online. [http://www.clinicaltrials.gov/ct2/show/N... ] Last accessed September 2012.
6. National Cancer Institute. Treatment Option Overview, Patient Version. Available online [http://www.cancer.gov/cancertopics/pdq/t... ]. Last accessed September 19, 2012.
7. National Cancer Institute. Metastatic Cancer: Questions and Answers. Available online [http://www.cancer.gov/cancertopics/factsheet/Sites-Types/met... ]. Last accessed September 19, 2012.
8. Dawood S et al. Survival differences among women with de novo stage IV and relapsed breast cancer. Annals of Oncology. 2010. 21: 2169-2174.
9. American Cancer Society. Treatment of invasive breast cancer, by stage. Last revised: November 22, 2010. Available Online [ http://www.cancer.org/Cancer/BreastCance... ]. Last accessed September 19, 2012.
CONTACTS
Media enquiries
David Ginivan
Tel: +44-1625-516973 mob: +44(0)-7775-412-619
Elizabeth Lockett
Tel: +44(0)20-3047-2078